Incyte Corporation
Incyte Corporation develops therapeutics for hematology/oncology, inflammation, and autoimmunity. Products include JAKAFI, MONJUVI, PEMAZYRE, ICLUSIG, ZYNYZ, and OPZELURA. Clinical-stage products include retifanlimab, axatilimab, INCA033989, and others. The company has collaborations with Novartis, Lilly, Agenus, Merus, MacroGenics, and Syndax. Products are sold to pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name in 2003. Incyte Corporation is headquartered in Wilmington, Delaware.
Overview
Strengths
- Creates economic value: ROIC of 27.1% against a cost of capital (WACC) of 7.6%, a spread of 19.5 percentage points.
- Pricing power: gross margin has held between 93% and 95% over the last 6 years (latest 92.8%).
- High-quality earnings: over the last 6 years, free cash flow added up to 109% of reported net income.
- Consistent growth: revenue has compounded at 14.0% a year over 5 years, rising every year.
- Shareholder-friendly capital allocation: the share count has shrunk by 3.8% a year over the last three years through buybacks.
- ROIC of 27.1% beats 83% of its 128 Biotechnology peers (median 0.0%).
Weaknesses
- Our discounted cash flow target price (83.24 USD) is 29% below the current price.
- Unstable profitability: operating margin ranged from -9% to 26% over the last 6 years, with operating losses in 1 of them.
- Earnings are projected to decline (-7.2% per year).
Key Financial Data